Boehringer

Novo Integrated Sciences’ Chief Medical Officer, Dr. Joseph M. Chalil, Selected as Top Physician of the Year by IAOTP

Retrieved on: 
Tuesday, April 26, 2022
Other Health, Software, General Health, Medical Devices, Technology, Hospitals, Marketing, Biotechnology, Communications, Practice Management, Other Technology, Health, Pillar, Health, Population, U.S. Securities and Exchange Commission, COVID-19, Security (finance), NASDAQ, Asian Americans, Science, Patient, Securities Exchange Act of 1934, Technology, Nova Southeastern University, Securities Act of 1933, Business, H. Wayne Huizenga College of Business and Entrepreneurship, MBA, Acceleration, Abbott Laboratories, Company, International Association, Boehringer, Solution, Entrepreneurship, Policy, DBV Technologies, American University of Integrative Sciences, Fellow, List, AAPI, MD, Leadership, Drug Quality and Security Act, American College, Hoffmann-La Roche, Allopathic medicine, Biotechnology, Health policy, Boehringer Ingelheim, Pharmaceutical industry, Medicine, Medical device, Public relations, Healthcare

Stephanie Cirami, IAOTP President, stated, We are honored to have Dr. Chalil as part of our IAOTP family.

Key Points: 
  • Stephanie Cirami, IAOTP President, stated, We are honored to have Dr. Chalil as part of our IAOTP family.
  • He is brilliant at what he does, has a unique understanding of health policies, and a diverse medical background.
  • Previously, Dr. Chalil has held roles of increasing responsibility at DBV Technologies, Boehringer Ingelheim, Abbott Laboratories, and Hoffmann-La Roche.
  • Innovation through science combined with the integration of sophisticated, secure technology assures Novo Integrated Sciences of continued cutting-edge advancement in patient first platforms.

 Inventiva announces that its IND application for the Phase II combination trial with lanifibranor and empagliflozin in patients with NASH and T2D has been accepted by the FDA

Retrieved on: 
Tuesday, March 8, 2022
Eli Lilly and Company, Risk, Private Securities Litigation Reform Act, Boehringer, Patient, Empagliflozin, Security (finance), Safety, Annual report, U.S. Securities and Exchange Commission, Eli Lilly, Cardiovascular disease, Lilly, Company, COVID-19, Disulfiram-like drug, Clinical trial, Type 2 diabetes, Intention, Review, Boehringer Ingelheim, Pharmaceutical industry

All statements, other than statements of historical facts, included in this press release are forward-looking statements.

Key Points: 
  • All statements, other than statements of historical facts, included in this press release are forward-looking statements.
  • Such statements are not historical facts but rather are statements of future expectations and other forward-looking statements that are based on management's beliefs.
  • Actual events are difficult to predict and may depend upon factors that are beyond Inventiva's control.
  • Consequently, Inventiva accepts no liability for any consequences arising from the use of any of the above statements.

Award: Boehringer Ingelheim is Global Top Employer 2022

Retrieved on: 
Thursday, January 20, 2022
Professional Services, Health, Human Resources, Research, Pharmaceutical, Science, MMH, Human, Ethics, Corporate headquarters, Solution, Boehringer Ingelheim, EUR, Human resources, Orientation, Certification, Boehringer, COVID, Management, Fine chemical

The Top Employers Institute awarded Boehringer Ingelheim for the second year in succession a Global Top Employer, one of the worlds eleven best employers.

Key Points: 
  • The Top Employers Institute awarded Boehringer Ingelheim for the second year in succession a Global Top Employer, one of the worlds eleven best employers.
  • Boehringer Ingelheim has been listed among the top employers in many countries and regions for the past eight years.
  • This year, Boehringer Ingelheim will receive the award in 29 countries, as well as in Europe and the Latin America, and Asia-Pacific regions.
  • The certification as Global Top Employer recognizes once again that our work environment makes the company stand out as an employer, says Dr Sven Sommerlatte, Global Head of Human Resources at Boehringer Ingelheim.

EUR 50 million for social businesses - Boehringer Ingelheim launches Boehringer Ingelheim Social Engagements

Retrieved on: 
Thursday, November 11, 2021
Professional Services, Health, Small Business, Environment, Finance, General Health, Program, Animal, EUR, Partnership, Board, Boehringer Ingelheim, MMH, Boehringer, Solution, Fine chemical

Boehringer Ingelheim announced today that it will dedicate EUR 50 million to a new initiative called Boehringer Ingelheim Social Engagements.

Key Points: 
  • Boehringer Ingelheim announced today that it will dedicate EUR 50 million to a new initiative called Boehringer Ingelheim Social Engagements.
  • Boehringer Ingelheim Social Engagements is dedicating 50 million Euros to help scale up solutions of social businesses to create systemic change, says Michael Schmelmer, Member of the Board of Managing Directors at Boehringer Ingelheim, announcing the initiative on the occasion of the Making More Health Together 2021 convention.
  • Boehringer Ingelheim Social Engagements is an extension of Boehringer Ingelheims flagship initiative, Making More Health (MMH).
  • Boehringer Ingelheim Social Engagements is now stepping up to provide financial support beyond typical corporate donations.

The Talent Enterprise: The Thriving Index® is Now a British Psychological Society (BPS) Registered Test

Retrieved on: 
Thursday, November 4, 2021
Personality, BPS, Sanofi, Ambiguity, UK, Europe and Africa Malankara Orthodox Diocese, Lighthouse, Deloitte, Ministry of Tourism (Saudi Arabia), ADQ, KPMG, Information technology, Saudi Arabia, Ministry, DHL, Dubai Holding, Machine learning, Al-Futtaim Group, COVID-19, Research, Tata Communications, Harvard Business Publishing, Chalhoub Group, Optimism, Science, NEOM, Acquisition, Asia, Empathy, Ministry of Communication and Information Technology (Saudi Arabia), Communication, Agility, Solution, Al-Rajhi Bank, The Saudi Investment Bank, Boehringer, DXC Technology, SAMI, Management, Risk management

DUBAI, UAE, Nov. 4, 2021 /PRNewswire/ -- The Talent Enterprise is absolutely delighted to announce that The Thriving Index® is now a BPS Registered Test. The tool is a product of over 10 years of research and large-scale validation studies and is used by over 250+ organisations across the world for their career guidance, talent acquisition, high potential identification, succession planning and leadership development priorities. The test registration status by the BPS reaffirms the scientific rigour, psychological research and international testing standards on which The Thriving Index® has been developed.

Key Points: 
  • DUBAI, UAE, Nov. 4, 2021 /PRNewswire/ -- The Talent Enterprise is absolutely delighted to announce that The Thriving Index is now a BPS Registered Test.
  • The test registration status by the BPS reaffirms the scientific rigour, psychological research and international testing standards on which The Thriving Index has been developed.
  • "The Thriving Index is grounded in the latest research and application of positive psychology and behavioural science and has many firsts.
  • SUMMARY: The Talent Enterprise's newest, BPS-registered psychometric assessment tool, The Thriving Index , is redefining recruitment and development.

The Talent Enterprise: The Thriving Index® is Now a British Psychological Society (BPS) Registered Test

Retrieved on: 
Thursday, November 4, 2021
Personality, BPS, Sanofi, Ambiguity, View, UK, Europe and Africa Malankara Orthodox Diocese, Lighthouse, Deloitte, Ministry of Tourism (Saudi Arabia), ADQ, KPMG, Information technology, Saudi Arabia, Ministry, DHL, Dubai Holding, Machine learning, Al-Futtaim Group, COVID-19, Multimedia, Research, Tata Communications, Harvard Business Publishing, Chalhoub Group, Optimism, Science, NEOM, Acquisition, Asia, Empathy, Ministry of Communication and Information Technology (Saudi Arabia), Communication, Agility, Solution, Al-Rajhi Bank, The Saudi Investment Bank, Boehringer, DXC Technology, SAMI, Management, Risk management

DUBAI, UAE, Nov. 4, 2021 /PRNewswire/ -- The Talent Enterprise is absolutely delighted to announce that The Thriving Index is now a BPS Registered Test.

Key Points: 
  • DUBAI, UAE, Nov. 4, 2021 /PRNewswire/ -- The Talent Enterprise is absolutely delighted to announce that The Thriving Index is now a BPS Registered Test.
  • The test registration status by the BPS reaffirms the scientific rigour, psychological research and international testing standards on which The Thriving Index has been developed.
  • "The Thriving Index is grounded in the latest research and application of positive psychology and behavioural science and has many firsts.
  • SUMMARY: The Talent Enterprise's newest, BPS-registered psychometric assessment tool, The Thriving Index , is redefining recruitment and development.

Boehringer Ingelheim and King’s College London Join Forces to Progress New Therapeutic Concepts in Major Depressive Disorder and Schizophrenia

Retrieved on: 
Wednesday, October 27, 2021
Biotechnology, Mental Health, Health, Pharmaceutical, Clinical Trials, Research, Polysomnography, Electroencephalography, III, SZ, Lists of diseases, Magnetic resonance, Memory, Drug discovery, Mental disorder, Sodium- and chloride-dependent glycine transporter 1, Boehringer Ingelheim, University College London Hospitals NHS Foundation Trust, Corporate headquarters, Life, Medicine, Government budget balance, Cognition, Trial of the century, Biomarker, Work, Attention, Emotion, Schizophrenia, Psychiatry, Solution, EEG, MDD, Institute of Psychiatry, Psychology and Neuroscience, Institute, Boehringer, Central nervous system, Psychology, Department, Neuroimaging, Pharmaceutical industry

Boehringer Ingelheim and the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at Kings College London today announced a new collaboration focused on understanding the malfunctions in brain circuits that drive impaired cognition in people with major depressive disorder (MDD) and schizophrenia (SZ).

Key Points: 
  • Boehringer Ingelheim and the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at Kings College London today announced a new collaboration focused on understanding the malfunctions in brain circuits that drive impaired cognition in people with major depressive disorder (MDD) and schizophrenia (SZ).
  • We are delighted to collaborate with Kings IoPPN, a leading institute for research in psychiatry, said Dr Vikas Mohan Sharma, Head of Medicine CNS, Retinopathies & Emerging Areas at Boehringer Ingelheim.
  • This collaboration will advance our understanding to better assess cognition and those biomarkers linked to cognitive deterioration in people with major depressive disorder and schizophrenia.
  • We look forward to jointly creating opportunities to accelerate future clinical trials and the development of treatments for the many people impacted by psychiatric disorders.

Boehringer Ingelheim Partners with Thoeris to Investigate a Novel Approach to Treat Urea Cycle Disorders

Retrieved on: 
Tuesday, October 26, 2021
Medical Devices, Health, Genetics, General Health, Pharmaceutical, Biotechnology, Quality of life, Blood, Cerebral edema, Drug development, UCD School of Medicine, RBB, Patient, Intellectual disability, Drug discovery, Boehringer Ingelheim, Doctor of Philosophy, Protein, CEO, Liver transplantation, UCD, Ingelheim am Rhein, Boehringer, Lethargy, Ammonia, Seizure, Pharmaceutical industry

Boehringer Ingelheim and Thoeris GmbH announce a collaboration and license agreement with the aim to investigate novel first-in-class therapies for patients with urea cycle disorders (UCDs).

Key Points: 
  • Boehringer Ingelheim and Thoeris GmbH announce a collaboration and license agreement with the aim to investigate novel first-in-class therapies for patients with urea cycle disorders (UCDs).
  • Thoeris has developed a novel approach that could transform the treatment of patients with these conditions.
  • Boehringer Ingelheim will contribute its expertise in drug discovery and development to advance potential medications into the clinic.
  • The new UCD therapy approach developed by Thoeris could enable disease symptom control by boosting a pathway to detoxify the excess ammonia levels in the body.

Boehringer Ingelheim increases commitments to sustainable development, investing in health innovation and collaborations to expand access and improve healthcare for 50 million people in vulnerable communities by 2030

Retrieved on: 
Monday, October 25, 2021
Health, Environment, Managed Care, General Health, Pharmaceutical, Biotechnology, OIE, Hospital, Vaccine, Hypertension, United Nations, Livestock, MORE, World Organization of Family Doctors, Human, Goal, Partnership, Patient, Dog, World, HEALTH, Boehringer Ingelheim, Corporate headquarters, Natural Resources, Board, Environment, Awareness, PharmAccess Foundation, Animal, Rabies, Health, Diabetes, Development, Boehringer, Prevalence, Parasitology, Renewable energy, Fine chemical, Pharmaceutical industry, Agriculture

Today, on the occasion of the World Health Summit 2021, Boehringer Ingelheim shares an update on its strategic approach to sustainable development.

Key Points: 
  • Today, on the occasion of the World Health Summit 2021, Boehringer Ingelheim shares an update on its strategic approach to sustainable development.
  • A commitment to initiatives that contribute to MORE HEALTH, one of the three pillars within the companys Sustainable Development - For Generations framework.
  • Continuing a journey that began more than 135 years ago, Boehringer Ingelheim is building on its track record in addressing unmet health needs, increasing the companys ambitions to tackle global health challenges.
  • It further evolves Boehringer Ingelheims commitments and significantly increases the companys contribution to positively impacting health, societal and environmental issues, in alignment with the United Nations 2030 Sustainable Development Goals.

Boehringer Ingelheim and Invetx Announce Strategic Collaboration to Advance Monoclonal Antibody Biotherapeutics in Animal Health

Retrieved on: 
Monday, September 27, 2021
Health, General Health, Research, Science, Pharmaceutical, Biotechnology, Veterinary, AbCellera, WuXi Biologics, Biotechnology, Cat, Partnership, Animal, Solution, Therapy, Animal Health, Health, Half-life, Multimedia, Heart, Immunotherapy, Environment, Boehringer Ingelheim Animal Health, Dog, Veterinary medicine, Antibody, LLC, Mab, Pain, Disease, Boehringer, Technology, Human, Cell, Doctor of Philosophy, Boehringer Ingelheim, Protein, Vaccine, Fine chemical, Invetx, Boehringer Ingelheim Animal Health, INVETX, BOEHRINGER INGELHEIM ANIMAL HEALTH

Boehringer Ingelheim, a global leader in animal health, and Invetx, a pioneer in protein-based therapeutics for animal health, are pleased to announce they have entered into a collaboration agreement to develop novel, species-specific monoclonal antibody (mAb) biotherapeutics targeting a wide range of diseases in the veterinary species, initially focused on dogs and cats.

Key Points: 
  • Boehringer Ingelheim, a global leader in animal health, and Invetx, a pioneer in protein-based therapeutics for animal health, are pleased to announce they have entered into a collaboration agreement to develop novel, species-specific monoclonal antibody (mAb) biotherapeutics targeting a wide range of diseases in the veterinary species, initially focused on dogs and cats.
  • This partnership is a prime example of Boehringer Ingelheims commitment to address unmet needs in the rapidly growing animal health market, shared Dr. Eric Haaksma, head of global innovation, animal health at Boehringer Ingelheim.
  • We were drawn to working with Invetx, in particular, because of the companys cutting-edge discovery platform, optimization technologies and antibody expertise.
  • Boehringer Ingelheim Animal Health is the second largest animal health business in the world, with net sales of 4.1 billion euros in 2020 and presence in more than 150 countries.